Acta Scientific Cancer Biology (ASCB)

Commentary Volume 4 Issue 7

Artemisinin and its Derivatives as Repurposing Drug against COVID-19

Kanchan Kumari and Sandip K Mishra*

Cancer Biology Laboratory, Department of Cancer Biology, Institute of Life Sciences (Department of Biotechnology, Govt of India), Bhubaneswar, Odisha, India

*Corresponding Author: Sandip K Mishra, Scientist-F, Cancer Biology Laboratory, Department of Cancer Biology, Institute of Life Sciences, Bhubaneswar, Odisha, India.

Received: June 04, 2020; Published: June 22, 2020


 The world is experiencing the outbreak of highly infectious RNA virus named COVID-19 or SARS-CoV-2 since December last year. As on 28 May 2020, World Health Organization (WHO) has reported 5,556,679 confirmed cases of COVID-19, including 351,866 deaths worldwide. Clinicians and scientists now know much about the characteristics of the virus and its effect on human health which is similar to SARC-CoV but with more serious outcomes.



  1. Guan WJ., et al. “Clinical Characteristics of Coronavirus Disease 2019 in China”. The New England Journal of Medicine (2020).
  2. Walls AC., et al. “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein”. Cell (2020).
  3. Rothe C., et al. “Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany”. The New England Journal of Medicine10 (2020): 970-971.
  4. Prompetchara E., et al. “Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic”. Asian Pacific Journal of Allergy and Immunology1 (2020): 1-9.
  5. Shi Y., et al. “COVID-19 infection: the perspectives on immune responses”. Cell Death and Differentiation (2020).
  6. Colson P., et al. “Chloroquine and hydroxychloroquine as available weapons to fight COVID-19”. International Journal of Antimicrobial Agents (2020): 105932.
  7. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. International Journal of Antimicrobial Agents (2020): 105949.
  8. Singh AK., et al. “Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries”. Diabetes and Metabolic Syndrome3 (2020): 241-246.
  9. Schrezenmeier E and Dorner T. “Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology”. Nature Reviews Rheumatology3 (2020): 155-166.
  10. Van den Borne BE., et al. “Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells”. The Journal of Rheumatology1 (1997): 55-60.
  11. Durcan L and Petri M. “Immunomodulators in SLE: Clinical evidence and immunologic actions”. Journal of Autoimmunity 74 (2016): 73-84.
  12. Lafyatis R., et al. “Antimalarial agents: closing the gate on Toll-like receptors?” Arthritis and Rheumatism 10 (2006): 3068-3070.
  13. Gerstein HC., et al. “The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial”. Diabetes Research and Clinical Practice3 (2002): 209-219.
  14. Izmirly PM., et al. “Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine”. Annals of the Rheumatic Diseases10 (2010): 1827-1830.
  15. Bloomgarden ZT. “Diabetes and COVID-19”. Journal of Diabetes4 (2020): 347-348.
  16. Zheng YY., et al. “COVID-19 and the cardiovascular system”. Nature Reviews Cardiology (2020).
  17. Acton N., et al. “Synthesis and antimalarial activity of some 9-substituted artemisinin derivatives”. Journal of Medicinal Chemistry17 (1993): 2552-2557.
  18. Jigang Wang CX., et al. “Artemisinin, the Magic Drug Discovered from Traditional Chinese Medicine”. Engineering, ScienceDirect, Elsevier 5.1 (2019): 32-39.
  19. Klayman DL. “Qinghaosu (artemisinin): an antimalarial drug from China”. Science4703 (1985): 1049-1055.
  20. Mojab F. “Antimalarial natural products: a review”. Avicenna Journal of Phytomedicine2 (2012): 52-62.
  21. Ma JD., et al. “A novel function of artesunate on inhibiting migration and invasion of fibroblast-like synoviocytes from rheumatoid arthritis patients”. Arthritis Research and Therapy1 (2019): 153.
  22. Organization WH. “Guidelines for the treatment of malaria”. 3rd Geneva:(WHO Press) (2015).
  23. Zhang T., et al. “Dihydroartemisinin regulates the immune system by promotion of CD8(+) T lymphocytes and suppression of B cell responses”. Science China Life Sciences (2019).
  24. Hou L and Huang H. “Immune suppressive properties of artemisinin family drugs”. Pharmacology and Therapeutics 166 (2016): 123-127.
  25. Ma RJ., et al. “Artemisinin and its derivatives: a potential therapeutic approach for oral lichen planus”. Inflammation research: official journal of the European Histamine Research Society4 (2019): 297-310.
  26. Yang Z., et al. “Immunomodulatory and anti-inflammatory properties of artesunate in experimental colitis”. Current Medicinal Chemistry26 (2012): 4541-4551.
  27. Li Z., et al. “Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do?” Molecules10 (2016).
  28. Charlie-Silva I., et al. “Progress in nano-drug delivery of artemisinin and its derivatives: towards to use in immunomodulatory approaches”. Artificial Cells, Nanomedicine, and Biotechnology3 (2018): S611-S620.
  29. Wang Wyfwh. “Immunomodulation of artemisinin and its derivatives”. Science Bulletin 18 (2016): 1399-1406.
  30. Bai L., et al. “Immunosuppressive effect of artemisinin and hydroxychloroquine combination therapy on IgA nephropathy via regulating the differentiation of CD4+ T cell subsets in rats”. International Immunopharmacology 70 (2019): 313-323.
  31. Liang N., et al. “Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-kappaB signaling pathway in lupus nephritis mice”. Experimental and Therapeutic Medicine3 (2018): 2436-2442.
  32. D'Alessandro S., et al. “The Use of Antimalarial Drugs against Viral Infection”. Microorganisms1 (2020).
  33. Paddon CJ., et al. “High-level semi-synthetic production of the potent antimalarial artemisinin”. Nature 7446 (2013): 528-532.


Citation: Kanchan Kumari and Sandip K Mishra. “Artemisinin and its Derivatives as Repurposing Drug against COVID-19”.Acta Scientific Cancer Biology 4.7 (2020): 21-23.


Acceptance rate35%
Acceptance to publication20-30 days
Impact Factor1.183

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US